Approval · Notice of Compliance 32049 · 2023
RIVA-DUTASTERIDE: Notice of Compliance 32049
Issued November 8, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32049
- Date
- November 8, 2023
- Company
- Laboratoire Riva Inc.Blainville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Admin
- Reason
- Administrative: Labelling Update (to match Licensor)
- Canadian reference product
- AVODART (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RIVA-DUTASTERIDE | Not yet assigned | — |
Medicinal ingredients
- DUTASTERIDE 0.5 MG per CAP